注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Cyclerion Therapeutics Inc是一家临床阶段的生物制药公司。该公司的主要资产CY6463是一种中枢神经系统(CNS)渗透剂、可溶性鸟苷酸环化酶(sGC)刺激剂,正在临床开发中,用于治疗阿尔茨海默病伴血管病变(ADv)、精神分裂症相关认知障碍(CIAS)、线粒体脑肌病、乳酸酸中毒和中风样发作(MELA)。CY6463是一种口服给药的CNS渗透剂sGC刺激器,正被开发为严重CNS疾病的症状和疾病调节疗法。其CNS资产CY3018是一种与CY6463相比具有CSF至血浆暴露的差异化CNS渗透剂sGC刺激器。CY3018专注于sGC刺激治疗中枢神经系统疾病。其非CNS资产包括Praliciguat和Olinciguat。Praliciguat是一种口服、每天一次的全身性sGC刺激器。Olinciguat是一种口服,每天一次的血管sGC刺激器。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Errol B. De Souza | 70 | 2021 | Independent Chairman |
Peter M. Hecht | 59 | 2019 | Director |
Mark G. Currie | 68 | 2019 | Chair of Scientific Advisory Board |
Terrance G. McGuire | 67 | 2019 | Independent Director |
Robert C. Malenka | - | 2021 | Member of Scientific Advisory Board |
Marni Joy Falk | - | 2021 | Member of Scientific Advisory Board |
David H. Salat | - | 2021 | Member of Clinical Advisory Board |
Daniela Salvemini | - | 2021 | Member of Scientific Advisory Board |
Andrew E. Budson | - | 2021 | Member of Clinical Advisory Board |
Claudio Babiloni | - | 2021 | Member of Scientific Advisory Board |
M Brandon Westover | - | 2021 | Member of Clinical Advisory Board |
Harald H. H. W. Schmidt | - | 2021 | Member of Scientific Advisory Board |
Steven E. Hyman | 72 | 2022 | Independent Director |
Eric Smith | - | 2021 | Member of Clinical Advisory Board |
Dina Katabi | - | 2023 | Director |
Michael J. Higgins | 62 | 2023 | Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核